Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aplastic anemia successfully treated with rituximab.

Per Boye Hansen1, Anne M Falensteen Lauritzen

  • 1Department of Internal Medicine F, Section of Hematology, Hillerød Hospital, Hillerød, Denmark. peboha@fa.dk

American Journal of Hematology
|November 30, 2005
PubMed
Summary

A 73-year-old female with aplastic anemia experienced a significant recovery after treatment with rituximab (anti-CD20 monoclonal antibody). This therapy normalized platelet and white blood cell counts, resolving transfusion dependence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.

Oncoimmunology·2024
Same author

Ugeskrift for laeger·2023
Same author

Retraction Note to: Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020
Same author

Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2016
Same author

[A 87-year-old woman was run down by a hit-and-run driver and cured of malignant lymphoma].

Ugeskrift for laeger·2016
Same author

[Malignant lymphoma complicated with posterior reversible encephalopathy].

Ugeskrift for laeger·2015

Area of Science:

  • Hematology
  • Immunology

Background:

  • A 73-year-old female presented with severe thrombocytopenia (12 x 10(9)/L) and easy bruising.
  • Initial investigations revealed parvovirus B19 infection history, normal karyotype, and absence of other viral or autoimmune markers.
  • Bone marrow examination showed erythroid hyperplasia and megakaryocytic hypoplasia, without malignancy.

Observation:

  • Initial treatment with prednisolone was ineffective.
  • Intravenous gamma-globulin therapy normalized platelet count temporarily.
  • Subsequent relapse led to transfusion-dependent anemia and leukopenia, diagnosed as aplastic anemia.

Findings:

  • Treatment with rituximab (anti-CD20 monoclonal antibody) resulted in sustained increases in platelet count (232 x 10(9)/L) and white blood cell count (6.8 x 10(9)/L).

Related Experiment Videos

  • The patient no longer required blood transfusions.
  • Bone marrow examination post-rituximab showed hyperplastic myelopoiesis and normoblastic erythropoiesis.

    • Implications:

    • Rituximab demonstrates potential efficacy in treating severe aplastic anemia.
    • Further investigation into anti-CD20 monoclonal antibody therapy for aplastic anemia is warranted.
    • This case highlights a potential therapeutic option for refractory aplastic anemia.